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*Day Hospital Ospedale Rasori, Azienda Ospedalieua, Pauma, Italy 
In order to characterize neutrophil and eosinophil presence in the airways of patients with chronic obstructive 
pulmonary disease (COPD), bronchoscopy with bronchial washings and bronchial biopsies was performed in 12 
smoking stable COPD subjects and 18 normal non-smoking control subjects. Bronchial biopsies were examined by 
light microscopy using plastic embedding and histochemical techniques to identify different cell types. 
Bronchial washing fluid of COPD patients was characterized by a predominance of neutrophils (P=O.OOl), and a 
slight, but significant (P=O.O3), increase of eosinophil fraction. Subjects with COPD had higher number of 
neutrophils in the epithelium (P=O.Ol), and eosinophils in the lamina propria (P=O.Ol) than did control subjects. 
The thickness of reticular basement membrane was increased for COPD patients in comparison to control subjects 
(P=O.Ol). 
The present study provides evidence of neutrophil infiltration both in bronchial washing and bronchial epithelium 
of patients with COPD, suggesting that the source of neutrophils in airway lumen may be the bronchial mucosa. 
Although less common than in asthma, airways of COPD subjects reveal eosinophil presence and airway 
remodelling. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is defined 
as a condition characterized by the presence of airflow 
obstruction due to chronic bronchitis or emphysema; the 
airflow obstruction is generally progressive, may be 
accompanied by airway hyperreactivity, and may be par- 
tially reversible (1). The pathological findings of COPD are 
characterized by goblet cell metaplasia, submucosal gland 
hypertrophy, and airway wall fibrosis and inflammation (2). 
The characteristics of the inflammatory reaction are differ- 
ent in bronchial tissue and at the epithelial surface of the 
airways: activated macrophages and T lymphocytes, pre- 
dominantly of the CD8 phenotype (3) together with mast 
cells, predominate in bronchial mucosa, in the interstitium 
and periglandular areas (4-10) while polymorphonuclear 
leukocytes have been found in increased proportions in the 
airway secretions (11-13) and in lavage fluid (1416). 
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Although current knowledge on the pathogenesis of this 
disorder does not provide convincing explanations for this 
discrepancy, it is clear that neutrophils can play a major 
role in inducing progressive airway damage. 
Studies which failed to show an increased number of 
neutrophils in bronchial mucosa of COPD patients (9,17- 
20) used immunocytochemical methods to identify neu- 
trophils. Immunohistochemistry is the most sensitive 
methodology to identify cells in tissue samples, however, 
the monoclonal antibodies available for neutrophil identi- 
fication have low specificity (21,22). For this reason, in this 
study as in previous studies (23,24), we used a simple 
histological technique to identify different cell types. 
In the present study, in order to characterize neutrophil 
and eosinophil presence in the airways of patients with 
COPD, bronchoscopy with bronchial washings and bron- 
chial biopsies was performed in 12 smoking stable COPD 
subjects and 18 normal non-smoking control subjects. 
Materials and Methods 
SUBJECTS 
Twelve smoking patients with COPD (11 males and one 
female, mean age 62.6 + 2.0 years) and 18 normal non- 
smoking subjects (13 males and five females, mean age 
0 1998 W. B. SAUNDERS COMPANY LTD 
864 A. PESCI ET AL. 
59.4 & 3.2 years) were included in the study. Subjects with 
COPD were characterized by cough and mucoid sputum 
production on most days of the month, for at least 3 
months per year during at least the previous 2 yr. The 
subjects met the following criteria: (1) no personal or family 
history of allergic disease; (2) no exacerbation of their 
disease, defined as increased dyspnoea associated with 
changes in quality (mucoid to purulent) and quantity of 
sputum within the preceding month; (3) no therapy with 
oral or inhaled glucocorticoids or inhaled cromolyn within 
3 months before entering the study; (4) forced expiratory 
volume in 1 s (FEVl) ~75% of predicted values, (5) no 
improvement in FEVl of over 15% after inhalation of 
200 pug of salbutamol, and (6) no history of systemic disease 
or of other pulmonary disease (patients with obvious 
emphysema, as assessed by routine chest X-ray studies were 
also excluded). Subjects were not excluded if they were 
receiving theophylline, P-agonists or both. 
All subjects underwent spirometric function tests 1 day 
before bronchoscopy (Spiroflow, Morgan, Kent, U.K). 
Blood eosinophils were counted on the same day as the 
pulmonary function tests. Their smoking history was care- 
fully checked, and a minimum of 15 pack-years smoked 
was required (16.5-80 pack-years, mean * SE: 38.6 k 6.7 
pack-years). 
The normal age-matched volunteers were asymptomatic 
lifelong non-smokers, without clinical or laboratory signs 
of sensitization to common allergens and normal spiromet- 
ric values. The volunteers were divided in two groups, the 
first group (ten subjects) performed only bronchial washing 
(BW), the second (eight subjects) only the bronchial biop- 
sies. The study protocol had the approval of the local ethics 
committee, and each person gave informed written consent 
before undergoing the bronchoscopic procedures. 
BRONCHOSCOPY PROCEDURES 
Bronchoscopy was performed between 8 and 9 a.m. on each 
occasion, according to National Institutes of Health Guide- 
lines (25). Subjects abstained from food for at least 12 h 
before bronchoscopy. Premeditation consisted of nebulized 
salbutamol (1.25 mg) and ipratropium bromide (0.5 mg), 
atropine (0.5 mg) by i.m. injection administered 30 min. 
before the procedure. Upper airways were anaesthetized by 
4 ml of lignocaine at 2%. Further lignocaine (1%) was 
administered, after flexible fibreoptic bronchoscope (1TlO 
Olympus, Tokyo, Japan) introduction, to the lower airways 
to suppress coughing. The bronchoscope was wedged into a 
segment of the right middle lobe, and one 50-ml aliquot of 
sterile saline solution, warmed at 37°C was infused. Fluid 
was gently aspirated immediately after the aliquot was 
introduced and collected in a sterile container (BW). This is 
corresponding to the first lavage sample of a bronchoalveo- 
lar lavage (BAL) which is considered more reflective of the 
content of conducting airways, whereas the further samples 
are more related to bronchioles and alveoli (26). 
Three bronchial specimens were taken with alligator 
forceps at the subcarinal level in the lower and middle lobes 
of the right lung. 
During the procedure, oximetry using a fingerprobe 
(Pulse Oxymeter 504, Critical Care System Inc., U.S.A.) 
and electrocardiograph (ECG) tracing were continuously 
monitored. Supplemental oxygen was delivered 
continuously via a nasal cannula at a rate of 3 1 min - ‘. 
HANDLING OF BW FLUID 
After recovery, BW fluid was strained through a monolayer 
of surgical gauze to remove mucus. The fluid was immedi- 
ately centrifuged at 800 rpm for 10 min. Supernatant was 
removed and the cell pellet was washed twice with 
phosphate-buffered saline (PBS) solution (without Ca*+ 
and Mg2+). Cytocentrifugates (Labofuge AE, Heraeus, 
Germany) were stained by the May-Grunwald-Giemsa 
method. The differential cell count of macrophages, lym- 
phocytes, neutrophils, and eosinophils was made under 
light microscopy at x 1000 (BH-2, Olympus), by counting 
approximately 300 cells in random fields. Results were 
expressed as percentage of total cells and as total number. 
HANDLING OF BRONCHIAL BIOPSY 
SPECIMENS 
The bronchial biopsy specimens were immediately fixed in 
periodate-lysine-paraformaldehyde (pH 7.4) for 3 h and 
then washed in a buffered cacodylate solution with 7% 
sucrose for 12 h. Each specimen was embedded in glycol 
methacrylate (JB4 Polysciences Inc., Newton, MA, U.S.A.). 
Tissue sections, 2,um thickness, were stained with 
haematoxylin-eosin and toluidine blue and examined under 
light microscopy at X 1000 magnification (S plan, 
Olympus). Two sections at lOOpurn intervals from each 
biopsy were selected and appropriately stained for each 
quantitation to avoid cell overlapping. 
Neutrophils, identified by their characteristic nucleus 
(multilobulated and hyperchromic without nucleoli) stain- 
ing with toluidine blue (Fig. l), eosinophils, identified by 
their eosinophilic staining, were then counted in the intact 
epithelium (as defined by the presence of both basal and 
columnar cells, with no appearance of metaplasia), and in 
the lamina propria (it was arbitrarily taken as a zone 80 pm 
deep to the limit of the reticular basement membrane, as 
defined by a squared eyepiece graticule). 
The thickness of the reticular basement membrane was 
assessed on the two sections stained with haematoxylin- 
eosin and was measured from the base of the bronchial 
epithelium to the outer limit of its reticular basement 
membrane at regular 200,um intervals along the length of 
each section, using a graduated eyepiece graticule. The final 
result was a single value per patient obtained from the 
averages of all measurements performed in two sections 
from each biopsy. The stained sections were coded and 
examined by a single-blinded investigator (A.P.). The cells 
were counted in adjacent non-overlapping high-power fields 
until all the available area was covered. 
The final result was a single value per patient obtained 
from the average of the measurements performed for each 
section. The cell counts were expressed as number of cells 
TABLE 1. Characteristics of patients with COPD and 18 healthy control subjects 
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Subject no. 
Age 
(years) Sex 
Blood 
Smoke eosinophils PaO, PaCO, FEVl FEVllFVC 
Atopy (pack-yr) n/X’ (mmHg) (mmHg) (% pred) W) 
COPD patients 
1 69 M No 50 120 72.2 44.7 71 66 
2 51 M No 17.5 410 78.4 34.8 75 70 
3 69 M No 55 40 70 44.6 74 69 
4 68 M No 50 170 65.1 45 74 68 
5 55 M No 40 170 68 38.2 75 71 
6 69 M No 40 330 66.6 46.3 70 70 
7 69 M No 51 170 65.4 49.8 75 68 
8 67 M No 50 240 71 43.8 73 64 
9 57 M No 80 140 78.9 34.5 60 57 
10 48 M No 16.5 120 71.6 40.5 61 58 
11 63 M No 24 80 65.3 46 70 60 
12 61 F No 24 60 72 45.3 75 65 
x mean 62.6 llM/lF - 38.6 170.8 70.8 42.7 71 65.5 
SE 2 6.7 31.5 1.4 1.3 1.5 1.4 
Healthy control subjects 
x mean 59.4 13M/5F No No 148.7 95.5 39.6 103.1 85 
SE 3.2 28.8 3.8 1.1 8.2 2 
per millimetre length of intact epithelium for the epithelial 
infiltrate, and as number of cells per square millimetre for 
the lamina propria. Microphotographs were taken using a 
35-mm microscope camera (PM-6, Olympus), and film 
(Kodak Ektachrome 64T professional) was used with 
semi-automatic controlled exposure times (EMM-7, 
Olympus). 
DATA ANALYSIS 
Group data were expressed as medians and range, or 
means & SE when appropriate. Comparisons between 
biopsy data of bronchitic and control subjects were made 
using the Mann-Whitney U test; Spearman rank test was 
used to examine the association of histological parameters 
with BW and physiological data; we accepted a P value 
~0.05 as indicating significance. The coefficient of repeat- 
ability, as described by Bland and Altman (27), was used to 
compare measurements performed on the two sections of 
the same biopsy. At least three replicate measurements of 
morphometric parameters were performed by the same 
observer, and the intra-observer reproducibility was 
assessed with the coefficient of variation for repeated 
measurements. 
Results 
Bronchoscopy with BW and endobronchial biopsies were Resin embedding of tissue permitted sections to be cut 
successfully performed and well tolerated in all subjects. much thinner (l-2pm) than paraffin sections, allowing 
CLINICAL FINDINGS 
The demographic characteristics of the subjects are pre- 
sented in Table 1. The mean age of patients with COPD and 
normal subjects was similar. The pulmonary function of 
normal subjects was within the normal range. All the 
patients with COPD had the FEVl 275% predicted, and 
the FEVl did not improve significantly after salbutamol 
inhalation. The total number of peripheral blood eosino- 
phils was similar for COPD and control subjects. All 
subjects were non-atopic, i.e. they had negative skin tests 
for common allergen extracts and no personal or family 
history of allergic disease. 
BRONCHIAL WASHING 
The number of cells and the differential counts in normal 
subjects and in patients with COPD are shown in Table 2. 
Neutrophils and eosinophils were significantly increased 
in patients with COPD in comparison with normal subjects. 
On the other hand, macrophages and lymphocytes were 
significantly reduced in COPD with respect to control 
subjects. Percentages of epithelial cells were similar in the 
COPD group compared with the group of controls 
(19.5 & 7.3 vs 13.2 * 6.4 n.s., respectively). In patients with 
COPD there was no correlation between smoking and any 
of these counts. 
BIOPSY FINDINGS 
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TABLE 2. Bronchial washing in COPD and control subjects 
Macrophages 
% no. X lo3 
Lymphocytes 
% no. x 103 
Neutrophils 
% no. X lo3 
Eosinophils 
% no. X lo3 
COPD patients 
Median 32.45 21.1 
Range 2.2-96.9 2.1-207.5 
Healthy control subjects 
Median 91.65 101 
Range 79.66100 63-l 30 
P 0.001 0.012 
1 0.75 63.2 62.6 
o-4.3 O-5.6 1.9-94.5 1.2-323 
2.65 3.9 
O-12.6 o-1 8.8 
0.041 0.027 
1.4 1.35 
O-12.8 O-19.2 
0.001 0.001 
1 1.6 
O-19.8 O-6.9 
0.2 0.15 
O-1.1 o-3.7 
0.032 0.035 
better optical definition of tissue and cell structure. Neu- 
trophils (Fig. 1) and eosinophils were easily identified in 
specimens of bronchial tissue. 
The coefficients of repeatability between measurements 
performed on the two sections of each biopsy were 0.76 
neutrophils, and 0.45 eosinophils mm - ’ for the epithelium, 
and 28.5 neutrophils, and 13.8 eosinophils mn-* for 
lamina propria. The mean coefficient of variation for three 
repeat cell counts by the same observer (A.P.) ranged from 
5% to 16% for the cells studied. The coefficient of variation 
of the assessment of the thickening of reticular basement 
membrane was 4%. 
Cell counts in biopsy specimens of COPD patients and 
control subjects are summarized in Table 3. 
Patients with COPD had an increased number of neu- 
trophils in epithelium (Fig. 2) when compared with control 
subjects, whereas the number of eosinophils was increased 
in the lamina propria (Fig. 3). The thickness of the reticular 
basement membrane, as assessed by light microscopy, was 
increased for COPD patients in comparison to control 
subjects (PcO.01) (Fig. 4). 
No correlations were found among data. 
FIG. 1. Light photomicrograph of several neutrophils in 
the bronchial epithelium, from a patient with COPD. 
Neutrophils are easily recognised by their multilobulated 
and hyperchromic nucleus (toluidine blue, original 
magnification: x 400). 
Discussion 
This study shows an increased number of neutrophils in the 
epithelium of living patients with COPD in comparison to 
normal healthy control subjects. In addition, an increased 
number of eosinophils in the lamina propria and thickness 
of the reticular basement membrane in the bronchial 
mucosa of the group of COPD patients are observed. 
Previous studies evaluating the inflammatory changes 
have demonstrated that the principal airway lumen change 
in patients with COPD, is an increase in the number of 
neutrophils (1 l-16) while there is a predominance of 
mononuclear cell infiltration in the mucosa (4-9). This 
discrepancy has given rise to the hypothesis that the luminal 
and the parenchymal inflammation may be different. Our 
observation permits us to hypothesize that the source of 
neutrophils in airway lumen of COPD patients is the 
bronchial mucosa and that lavage findings reflect the 
pathology of airway mucosa, and in particular its 
epithelium. This confirms recent findings published in 
preliminary form (20). 
It can be argued that a larger percentage of neutrophils 
was observed in bronchial lumen than was observed in 
bronchial mucosa of our COPD patients, and that no 
correlation was found between the percentage of neu- 
trophils in BW and that in bronchial mucosa. However, it 
may be unreasonable to expect that the findings of sputum, 
bronchial washing, and bronchoalveolar lavage would 
closely mimic those of biopsies of COPD patients given 
the dynamic nature of the inflammatory response and the 
differences in cell populations found on either side of the 
epithelial basement membrane of the normal lung. Static 
histopathological examination of migratory cells such as 
neutrophils and eosinophils would be expected to show 
only those cells presently in transit between the blood and 
the bronchial lumen, whereas lavage fluids would better 
reflect the magnitude of cell migration into the bronchus 
over time. There is every reason to think that histopatho- 
logical and lavage fluid findings will be complementary and 
mutually informative in studying bronchial disorders. 
The increased number of neutrophils in the epithelium 
and the absence of any statistical difference in their number 
in the lamina propria of COPD patients in comparison to 
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TABLE 3. Endobronchial biopsy in COPD and control subjects 
i 
RBM 
fim 
Epithelium (cells mm - ‘) 
Neutrophils Eosinophils 
Lamina P (cells mm - ‘) 
Neutrophils Eosinophils 
COPD patients 
Median 6 2.15 0 
Range 3.6-8.6 0416.9 o-3.1 
Healthy control subjects 
Median 4.3 0.9 0 
Range 3.8-5.2 o-1.9 O-1.3 
P 0.01 0.01 ns. 
39.2 26.6 
12.7-149.3 9.8-60.3 
22.85 4.45 
7.6-59.2 0.33 
n.s. 0.01 
RBM, reticular basement membrane; Lamina P, lamina propria. 
P = 0.01 
I 
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FIG. 2. Neutrophils and eosinophils in the epithelium of 
control and COPD subjects. Horizontal bars represent 
group median values. 
control subjects could sustain the hypothesis that 
epithelium-derived factors linked to the disease state are 
crucial to the retention of neutrophils within the epithelium. 
In this regard, interleukin-8 (IL-8) a potent neutrophil 
chemoattractant and activator, which can be produced by 
epithelial cells (28), was found increased in sputum (13) and 
bronchial washing (29) in COPD. 
The concentration of neutrophils in BAL fluid has been 
reported to be negatively correlated with the FEVl (14-16) 
and positively with smoking history (14,16,19). We were 
unable to observe any significant correlation between neu- 
trophil counts and the number of pack-years smoked, or 
FEVl. This may be due to the relatively small number of 
c 
COPD Controls 
P = 0.01 
1 
0 
: 
0 
l -- .- 
l 
l oe 0. 00 0 
COPD Controls 
FIG. 3. Neutrophils and eosinophils in the lamina propria 
of control and COPD subjects. Horizontal bars represent 
group median values. 
subjects that we examined, the different selection criteria of 
patients, the difference in airway sampling, and to the 
difficulties in correctly assessing the numbers of cigarettes 
smoked over very long periods of time. In any case, larger 
populations of COPD and control smoking subjects may be 
required to clarify associations between neutrophil inflam- 
mation, smoking history, and airway obstruction. Previous 
studies examining the percentages of macrophages and 
lymphocytes in bronchial lumen of COPD patients reported 
conflicting results (see 10,14,16 and 17). The reduced per- 
centages of macrophages and lymphocytes in bronchial 
washing of our COPD patients may be explained by the 
elevation of neutrophils in the same compartment. The 
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FIG. 4. Thickness of reticular basement membrane of 
control and COPD subjects. Horizontal bars represent 
group median values. 
mechanism that causes neutrophil accumulation remains 
speculative, but some possibilities can be postulated. 
Recently, increased expression of the adhesion molecules 
intercellular adhesion molecule-l (ICAM-1) and E-selectin 
(30) in the endothelium has been shown on bronchial 
biopsy of patients with COPD, and tumour necrosis 
factor-a, a cytokine known to upregulate adhesion mol- 
ecules, has been demonstrated to be elevated in induced 
sputum of patients with COPD in addition to the potent 
neutrophil attractant and activator IL-8 (13). 
The eosinophil findings support previous observations 
(16,17,3 1) and confirm that some eosinophils are present in 
the airways of the subjects with stable COPD, although this 
is far less common than in asthma (32,33). Eosinophil- 
directed haematopoietins, granulocyte macrophage-colony 
stimulating factor (GM-CSF)- and IL-3, or interferon-y 
produced by T-lymphocytes may increase eosinophils in 
tissues by prolonging their survival (34,35). This mechanism 
is conceivable in chronic bronchitis where activated lym- 
phocytes in bronchial mucosa were demonstrated (9). 
Moreover, recent studies (31,36) demonstrated an effect of 
bronchial eosinophilia on airtlow obstruction in patients 
with COPD. In particular, Nagai et al. (36) showed that in 
COPD patients flow rates are adversely affected by bron- 
chial eosinophilia. Chanez et al. (31) demonstrated that 
corticosteroid reversibility in COPD patients is related to 
the presence of eosinophilic inflammation in the airways of 
these subjects. 
Reticular basement membrane thickness in COPD 
patients was increased, but to a lesser extent than in 
asthmatic subjects analysed with the same methodology 
(37). Our data confirm the observations of Lacoste et al. 
(17) who showed an increase of reticular basement mem- 
brane thickness in most patients with chronic obstructive 
pulmonary disease, and differ from those of Saetta et al. (9), 
Ollerenshaw et al. (38) and Trevisani et al. (39) who did not 
observe significant differences of reticular basement mem- 
brane size in comparison to control subjects. The different 
findings of these studies may be explained by the different 
populations (different degrees of obstruction, different dis- 
ease duration) of chronic bronchitis patients evaluated or 
by different methodology used. The thickness of reticular 
basement membrane in our COPD patients is similar to 
that of control subjects in most of the reports of the 
literature, this may be explained by the fact that in the 
present study bronchial biopsy specimens were embedded 
in glycol methacrylate whereas in the other studies 
paraffin embedding has been used, which is known to cause 
shrinkage of the tissue samples. 
It is reasonable to postulate that the thickness of reticular 
basement membrane in COPD could contribute to airway 
obstruction. In fact, airway obstruction in chronic bronchi- 
tis has a multifactorial pathogenesis and is linked not only 
to acute inflammatory events like tissue oedema, and cell 
infiltration, but also to irreversible end-stage lesions such 
as a connective tissue deposition, and distortion of the 
membranous bronchioles by loss of elastic recoil (40). 
Our observations of an increased number of eosinophils 
and thickness of reticular basement membrane in bronchial 
mucosa of COPD patients nicely fit with the ‘Dutch 
hypothesis’, that considers asthma and COPD to be differ- 
ent expressions of the same disease. In any case, larger 
populations of COPD patients may be required to establish 
if the presence of a thick reticular basement membrane and 
eosinophils in biopsy sections may differentiate asthma 
from COPD. 
In conclusion, the present study provides evidence for 
neutrophil and eosinophil infiltration in bronchial mucosa 
of COPD patients, supporting the involvement of these cells 
in the pathogenesis of the disease. 
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